LigaChem Biosciences Welcomes New Chief Medical Officer
LigaChem Biosciences, Inc. (KOSDAQ: 141080), a pioneer in the innovative field of antibody-drug conjugates (ADCs) for cancer treatment, is excited to announce the appointment of Dr. Rodrigo Ruiz Soto as its Chief Medical Officer (CMO). In this integral role, Dr. Ruiz Soto will spearhead the clinical strategy and contribute significantly to the advancement of their promising pipeline of therapeutic candidates aimed at improving patient outcomes.
A Decade of Experience in Oncology
Dr. Ruiz Soto brings over two decades of extensive experience in oncology clinical development, previously holding senior roles at leading biopharmaceutical firms. Most recently, at Deciphera Pharmaceuticals, he was the Senior Vice President of Clinical Development, where he guided the successful global approval of Ripretinib among other advancements in small molecules. His broad expertise spans various oncology indications, encompassing solid tumors and hematological malignancies.
Leadership in Clinical Development
“Rodrigo is an accomplished leader with a proven track record in clinical development,” stated Yong-Zu Kim, the CEO of LigaChem Biosciences. “His vast experience and in-depth insights into oncology are invaluable as we push forward with our clinical programs, aiming to bring innovative therapies to patients.” The addition of Dr. Ruiz Soto to the team represents a pivotal moment for LigaChem as they navigate the complexities of clinical advancements.
Previous Roles and Achievements
Before his impactful stint at Deciphera, Dr. Ruiz Soto was Senior Medical Director at ImmunoGen, Inc., where he played a vital role as the medical lead for the Mirvetuximab Soravtansine program, achieving FDA approval in 2022. His previous tenure at Sanofi Oncology saw him overseeing crucial clinical developments within a range of oncology trials, including advanced studies on a pan-PI3K inhibitor and mTOR pathways.
Vision for Future Development
“Joining LigaChem Biosciences at this exciting juncture is a thrilling opportunity,” expressed Dr. Ruiz Soto. “I am eager to collaborate with the talented team to drive our promising therapeutic pipeline forward, contributing to the development of innovative treatments that can significantly impact patients' lives.” His vision aligns perfectly with LigaChem's commitment to leveraging antibody-drug conjugates in the battle against cancer, thereby enhancing patient care.
Location and Organizational Growth
Dr. Ruiz Soto will officially begin as CMO, operating from AntibodyChem Biosciences, Inc., the company’s U.S. subsidiary located in Massachusetts. This appointment is set against a backdrop of organizational growth and an expanding clinical portfolio, demonstrating LigaChem’s commitment to tackling challenging cancer indications through innovative therapies.
About LigaChem Biosciences
LigaChem Biosciences remains unwavering in its mission to discover and develop groundbreaking therapies that utilize the power of antibody-drug conjugates in addressing cancer and other severe illnesses. Their overarching aim is to elevate the quality of life for patients, delivering effective and targeted treatment solutions. For more information about LigaChem's innovative approach, please visit their official website.
Frequently Asked Questions
Who is the new Chief Medical Officer at LigaChem Biosciences?
Dr. Rodrigo Ruiz Soto has been appointed as the Chief Medical Officer.
What experience does Dr. Ruiz Soto bring to the company?
He has over 20 years of experience in oncology clinical development, with significant roles in notable biopharmaceutical companies.
What was Dr. Ruiz Soto's role at Deciphera Pharmaceuticals?
He served as the Senior Vice President of Clinical Development, leading successful clinical initiatives.
Where will Dr. Ruiz Soto be based?
He will be based at AntibodyChem Biosciences, Inc., the U.S. subsidiary of LigaChem Biosciences.
What is LigaChem's focus in the biopharmaceutical industry?
LigaChem focuses on developing innovative antibody-drug conjugates for treating cancer and serious diseases, aiming to enhance patient quality of life.
